[Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].
- 1The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, National Health Commission Key Laboratory of Thrombosis and Hemostasis, Suzhou 215006, China.
Abstract
Objective: To analyze the mutational characteristics and prognosis of patients with myeloid neoplasms and SF3B1 mutations. Methods: This retrospective cohort study analyzed clinical data from 183 patients with myeloid neoplasms and SF3B1 mutations diagnosed at the First Affiliated Hospital of Soochow University from October 2016 to December 2024. High-throughput sequencing was used to detect mutations in 52 common genes associated with myeloid neoplasms, and the patients' mutational characteristics were examined. Results: A total of 31 types of SF3B1 mutations were detected in the present study. SF3B1 mutations mainly occurred within the HEAT domain, spanning amino acids 581 to 933. The median number of gene mutations in patients with myelodysplastic neoplasms (MDS) [2 (1-7) ] was lower than that in patients with SF3B1-mutated myelodysplastic/myeloproliferative neoplasms (MDS/MPN) [4 (1-9) ] and acute myeloid leukemia (AML) [3 (1-9) ], with all differences being significant (all P<0.001). Among patients with clonal hematopoiesis and MDS with <5% blasts, those with an SF3B1 mutational variant allele frequency (VAF) of <10% had higher median HGB levels than those with an SF3B1 mutation VAF of ≥10% (95 g/L vs 76 g/L, P=0.002). Patients with an SF3B1 mutation VAF of <10% had a lower median percentage of ring sideroblasts than those with an SF3B1 mutation VAF of ≥10% (3% vs 41%, P<0.001). Furthermore, the incidence of JAK2 V617F mutations was higher in the MDS/MPN patients than in the MDS patients (22.2% vs 1.2%, P=0.001), as was the incidence of RUNX1 mutations (33.3% vs 6.6%, P=0.002). The incidence of RUNX1 mutation was higher in AML patients than in MDS patients (24.2% vs 6.6%, P=0.008), as was the RAS family gene mutations (66.7% vs 3.8%, P<0.001). In MDS and MDS/MPN, patients with RUNX1 mutations had a higher risk of progression to AML than those without such a mutation (P<0.001). Patients with MDS-SF3B1 (91.6%) and MDS/MPN (79.9%) demonstrated better 5-year overall survival than those with AML (63.8%) (P< 0.001 and P=0.033, respectively). Conclusion: Patients with different subtypes of SF3B1-mutated myeloid neoplasms exhibit distinct mutational profiles and prognoses.
Related
- Characteristics and prognosis of Herpesviridae-related pneumonia in critically ill burn patients
- Karyotypic complexity and mutated TP53 are associated with myeloid neoplasms with ring chromosomes.
- Lesion Morphological Characteristics and Prognosis of Non-ST-Elevation Myocardial Infarction Patients With Different Types of Culprit Artery
- Clinical characteristics and prognosis of liver injury in patients receiving immune checkpoint inhibitor-based therapy: a real-world retrospective study
- [Clinical characteristics and prognosis of patients with direct antiglobulin test-negative autoimmune hemolytic anemia].
BibTeX
@article{zhang2026mutation,
title = {{[Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].}},
author = {H M Zhang and N Wu and A R Jiang and J D Xie and H Yao and Q Wang and D D Liu and J L Pan and Z X Chen and S N Chen and H J Shen},
journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
year = {2026},
month = aug,
doi = {10.3760/cma.j.cn121090-20260303-00116},
url = {https://europepmc.org/article/MED/42851180},
note = {CC BY},
}
RIS
TY - JOUR
TI - [Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].
AU - H M Zhang
AU - N Wu
AU - A R Jiang
AU - J D Xie
AU - H Yao
AU - Q Wang
AU - D D Liu
AU - J L Pan
AU - Z X Chen
AU - S N Chen
AU - H J Shen
PY - 2026
DA - 2026/08/01
JO - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
DO - 10.3760/cma.j.cn121090-20260303-00116
UR - https://europepmc.org/article/MED/42851180
AB - Objective: To analyze the mutational characteristics and prognosis of patients with myeloid neoplasms and SF3B1 mutations. Methods: This retrospective cohort study analyzed clinical data from 183 patients with myeloid neoplasms and SF3B1 mutations diagnosed at the First Affiliated Hospital of Soochow University from October 2016 to December 2024. High-throughput sequencing was used to detect mutations in 52 common genes associated with myeloid neoplasms, and the patients' mutational characteristics were examined. Results: A total of 31 types of SF3B1 mutations were detected in the present study. SF3B1 mutations mainly occurred within the HEAT domain, spanning amino acids 581 to 933. The median number of gene mutations in patients with myelodysplastic neoplasms (MDS) [2 (1-7) ] was lower than that in patients with SF3B1-mutated myelodysplastic/myeloproliferative neoplasms (MDS/MPN) [4 (1-9) ] and acute myeloid leukemia (AML) [3 (1-9) ], with all differences being significant (all P<0.001). Among patients with clonal hematopoiesis and MDS with <5% blasts, those with an SF3B1 mutational variant allele frequency (VAF) of <10% had higher median HGB levels than those with an SF3B1 mutation VAF of ≥10% (95 g/L vs 76 g/L, P=0.002). Patients with an SF3B1 mutation VAF of <10% had a lower median percentage of ring sideroblasts than those with an SF3B1 mutation VAF of ≥10% (3% vs 41%, P<0.001). Furthermore, the incidence of JAK2 V617F mutations was higher in the MDS/MPN patients than in the MDS patients (22.2% vs 1.2%, P=0.001), as was the incidence of RUNX1 mutations (33.3% vs 6.6%, P=0.002). The incidence of RUNX1 mutation was higher in AML patients than in MDS patients (24.2% vs 6.6%, P=0.008), as was the RAS family gene mutations (66.7% vs 3.8%, P<0.001). In MDS and MDS/MPN, patients with RUNX1 mutations had a higher risk of progression to AML than those without such a mutation (P<0.001). Patients with MDS-SF3B1 (91.6%) and MDS/MPN (79.9%) demonstrated better 5-year overall survival than those with AML (63.8%) (P< 0.001 and P=0.033, respectively). Conclusion: Patients with different subtypes of SF3B1-mutated myeloid neoplasms exhibit distinct mutational profiles and prognoses.
SN - 0253-2727
SN - 2707-9740
ER -